The mRNA vaccines and therapeutics market is poised for robust growth, driven by expanding applications beyond COVID-19, ...
Moderna’s mRNA flu vaccine gave more protection against illness than the standard flu shot in a phase 3 clinical trial, according to published results.
After getting slapped with a surprise refuse-to-file letter signed by former CBER Director Vinay Prasad, Moderna’s flu ...
SEOUL, South Korea--(BUSINESS WIRE)--Lemonex Inc., a biotechnology company developing innovative messenger RNA (mRNA) and siRNA therapeutics based on a novel nanoparticle drug delivery system ...
Dublin, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The "mRNA Therapeutics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for mRNA Therapeutics ...
In December 2025, Moderna submitted an application to the FDA to approve the first mRNA-based flu vaccine. Catherine Falls Commercial/Moment via Getty Images Ana Santos Rutschman, Villanova University ...
Moderna, Inc. (NASDAQ:MRNA) today announced that it had voluntarily withdrawn the pending Biologics License Application (BLA) seeking approval for its COVID-19 and Influenza combination vaccine for ...
In December 2025, Moderna submitted an application to the FDA to approve an mRNA flu vaccine for adults age 50 and older. The vaccine had been tested in clinical trials including more than 40,000 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results